Antagonism of endothelin actions

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 38/18 (2006.01) A61K 31/505 (2006.01) A61K 31/70 (2006.01) A61K 38/06 (2006.01) A61K 38/10 (2006.01) A61K 38/12 (2006.01) A61K 38/14 (2006.01) A61K 38/22 (2006.01) A61K 48/00 (2006.01)

Patent

CA 2248047

The mechanism of hypertension following acute NO synthase blockade is via endothelin-mediated vasoconstriction. Thus, NO appears to inhibit endothelin activity by blocking its expression and not as a chronic direct acting vasodilator. Administration of an endothelin antagonist to a patient in a 'normal' physiological state may result in specific regional vasodilation. This treatment finds utility in the treatment of erectile dysfunction.

Le mécanisme d'hypertension qui suit le blocage aigu de la NO synthase se traduit par une vasoconstriction induite par l'endothéline. Donc, NO semble inhiber l'activité de l'endothéline par le blocage de son expression et non par l'action directe d'un vasodilatateur chronique. L'administration d'un antagoniste de l'entodhéline à un patient présentant un état physiologique "normal" peut entraîner une vasodilatation régionale spécifique. Ce traitement s'avère être utile pour traiter la dysérection.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Antagonism of endothelin actions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antagonism of endothelin actions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonism of endothelin actions will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1838354

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.